Antibody–Drug Conjugates with Indolinobenzodiazepine Dimer Payloads: DNA-Binding Mechanism of Indolinobenzodiazepine Dimer Catabolites in Target Cancer Cells
Open Access
- 19 November 2019
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 17 (1) , 50-58
Abstract
The DNA-targeting indolinobenzodiazepine dimer (IGN) payloads are used in several clinical-stage antibody-drug conjugates (ADCs). IGN drugs alkylate DNA through the single imine moiety present in the dimer, in contrast to the pyrrolobenzodiazepine dimer (PBD) drugs, such as talirine and tesirine, which contain two imine moieties per dimer and are DNA cross-linking. This study explored the mechanism of binding of IGN to DNA in cells and to synthetic duplex and hairpin oligonucleotides. New, highly sensitive IGN-DNA binding ELISA methods were developed using biotinylated IGN analogs (monoimine, diimine, and diamine IGNs) and digoxigenin-labeled duplex oligonucleotides, which allowed the measurement of drug-DNA adducts in viable cells at concentrations below IC50. Furthermore, the release of free drug from the IGN-DNA adduct upon treatment with nuclease ex vivo was tested under physiological conditions. The monoimine IGN drug formed highly stable adduct with DNA in cells, with stability similar to that of the diimine drug analog. Both monoimine and diimine IGN-DNA adducts released free drugs upon DNA cleavage by nuclease at 37 °C, although more free drug was released from the monoimine compared to the diimine adduct, which presumably was partly cross-linked. The strong binding of the monoimine IGN drug to duplex DNA results from both the non-covalent IGN-DNA interaction and the covalent bond formation between the 2-amino group of a guanine residue and the imine moiety in IGN.Keywords
This publication has 30 references indexed in Scilit:
- Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic IndexClinical Cancer Research, 2019
- A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cellsBlood Advances, 2018
- A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody–Drug Conjugates (ADCs)Molecular Cancer Therapeutics, 2018
- Antibody–Drug Conjugates for Cancer TreatmentAnnual Review of Medicine, 2018
- The antibody–drug conjugate target landscape across a broad range of tumour typesAnnals of Oncology, 2017
- From Anthramycin to Pyrrolobenzodiazepine (PBD)‐Containing Antibody–Drug Conjugates (ADCs)Angewandte Chemie International Edition, 2016
- A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating ActivityMolecular Cancer Therapeutics, 2016
- Design and Synthesis of Tesirine, a Clinical Antibody–Drug Conjugate Pyrrolobenzodiazepine Dimer PayloadACS Medicinal Chemistry Letters, 2016
- Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and MonkeysClinical Cancer Research, 2011
- Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignanciesBlood, 2004